Traders bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Thursday. $238.37 million flowed into the stock on the tick-up and $160.23 million flowed out of the stock on the tick-down, for a money net flow of $78.14 million into the stock. Of all companies tracked, Gilead Sciences had the 10th highest net in-flow for the day. Gilead Sciences traded down ($2.01) for the day and closed at $77.88
A number of analysts have recently issued reports on the company. Jefferies Group LLC reaffirmed a “hold” rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 11th. Leerink Swann lifted their target price on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research report on Thursday, October 19th. BMO Capital Markets reaffirmed an “outperform” rating and set a $82.00 target price (up from $72.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Thursday, July 13th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.64.
The company has a 50 day moving average of $82.38 and a 200 day moving average of $72.98. The stock has a market cap of $101.71 billion, a PE ratio of 8.46 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, October 30th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the prior year, the firm earned $2.75 earnings per share. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post $8.79 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.67%. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock worth $36,338,919 over the last three months. 1.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the last quarter. Penserra Capital Management LLC grew its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the last quarter. Webster Bank N. A. grew its stake in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $143,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $147,000. 73.88% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/26/investors-buy-shares-of-gilead-sciences-inc-gild-on-weakness.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.